News
-
-
-
PRESS RELEASE
Cantourage Group SE increases EBITDA by 45 percent in the second quarter of 2026 – strategic focus on high-margin business pays off
Cantourage Group SE increases EBITDA by 45% in Q2 2026, focusing on high-margin products to boost profitability. UK and Poland show strong growth, enhancing revenue diversification -
-
-
PRESS RELEASE
Cantourage welcomes clarification on the implementation of the German GKV-FinStG
Cantourage Group SE welcomes clarification on the implementation of the German GKV-FinStG by KBV and GKV-Spitzenverband, ensuring continuity of treatment with cannabis extracts. CEO Philip Schetter emphasizes legal certainty benefits for patients and physicians -
-
-
PRESS RELEASE
Original-Research: Cantourage Group SE (von First Berlin Equity Research GmbH): Kaufen
First Berlin Equity Research reaffirms BUY rating on Cantourage Group SE with €11 target price after the launch of 'gramz.' proprietary product for the German MedCan market. Strategic shift to direct sourcing for higher margins -
